# ChiCGB vs BEAM in High-risk or R/R Lymphomas

> **NCT05466318** · PHASE3 · UNKNOWN · sponsor: **Sichuan University** · enrollment: 306 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, T-Cell

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Cladribine
- **DRUG:** Gemcitabine
- **DRUG:** Busulfan
- **DRUG:** Carmustine
- **DRUG:** Etoposide
- **DRUG:** Cytarabine
- **DRUG:** Melphalan
- **PROCEDURE:** Autologous hematopoietic stem cell transplant

## Key facts

- **NCT ID:** NCT05466318
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 306 (ESTIMATED)
- **Last updated:** 2022-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05466318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05466318, "ChiCGB vs BEAM in High-risk or R/R Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05466318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*